Literature DB >> 30232739

Comment on: "Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs".

Courtney M Suggs1, Robert L Levin2, Andrew D Mosholder2, Richard S Swain2, Liang Zhao2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30232739     DOI： 10.1007/s40264-018-0726-3

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  13 in total

1.  Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded.

Authors:  Amanda R Patrick; Matthew Miller; Catherine W Barber; Philip S Wang; Claire F Canning; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-10-03       Impact factor: 2.890

2.  Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.

Authors:  Kelly Posner; Maria A Oquendo; Madelyn Gould; Barbara Stanley; Mark Davies
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

3.  Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.

Authors:  J Bohn; C Kortepeter; M Muñoz; K Simms; S Montenegro; G Dal Pan
Journal:  Clin Pharmacol Ther       Date:  2015-04-03       Impact factor: 6.875

4.  Monitoring suicidal patients in primary care using electronic health records.

Authors:  Heather D Anderson; Wilson D Pace; Elias Brandt; Rodney D Nielsen; Richard R Allen; Anne M Libby; David R West; Robert J Valuck
Journal:  J Am Board Fam Med       Date:  2015 Jan-Feb       Impact factor: 2.657

5.  The association between income and distress, mental disorders, and suicidal ideation and attempts: findings from the Collaborative Psychiatric Epidemiology Surveys.

Authors:  Katherine A McMillan; Murray W Enns; Gordon J G Asmundson; Jitender Sareen
Journal:  J Clin Psychiatry       Date:  2010-04-06       Impact factor: 4.384

6.  Identifying suicidal behavior among adolescents using administrative claims data.

Authors:  S Todd Callahan; D Catherine Fuchs; Richard C Shelton; Leanne S Balmer; Judith A Dudley; Patricia S Gideon; Michelle M Deranieri; Shannon M Stratton; Candice L Williams; Wayne A Ray; William O Cooper
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-02-15       Impact factor: 2.890

7.  Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.

Authors:  Ning Cheng; Md Motiur Rahman; Yasser Alatawi; Jingjing Qian; Peggy L Peissig; Richard L Berg; C David Page; Richard A Hansen
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

8.  An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.

Authors:  Geetha Iyer; Sathiya Priya Marimuthu; Jodi B Segal; Sonal Singh
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.228

9.  Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use.

Authors:  Hyungjin Myra Kim; Eric G Smith; Claire M Stano; Dara Ganoczy; Kara Zivin; Heather Walters; Marcia Valenstein
Journal:  BMC Health Serv Res       Date:  2012-01-23       Impact factor: 2.655

Review 10.  Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.

Authors:  Marc Stone; Thomas Laughren; M Lisa Jones; Mark Levenson; P Chris Holland; Alice Hughes; Tarek A Hammad; Robert Temple; George Rochester
Journal:  BMJ       Date:  2009-08-11
View more
  1 in total

1.  Authors' Reply to Courtney Suggs and Colleagues' Comment on: "Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs".

Authors:  Richard A Hansen; Ning Cheng; Md Motiur Rahman; Yasser Alatawi; Jingjing Qian; Peggy L Peissig; Richard L Berg; C David Page
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.